Fixed combination therapies based on direct renin inhibition: a commentary to the ACCELERATE trial

摘要

Despite the Well-established concept that the treatment of high blood pressure (BP) represents a key strategy in reducing the burden of cardiovascular (CV) and renal diseases, arterial hypertension remains poorly controlled worldwide. To improve BP control in the hypertensive population, a more extensive use of combination therapies rather than monotherapies should be adopted, even as a first-line approach, in patients with grade 2-3 hypertension, in high-risk individuals or in those who need more ambitious BP goals (e.g., diabetics). Today, this represents an emerging clinical strategy for the daily clinical practice of hypertension, since recent randomized clinical trials have demonstrated the efficacy, safety and tolerability of such therapeutic approach.